RCC1 knockdown sensitizes drug-resistant colorectal cancer to 5-fluorouracil or doxorubicin by impairing DNA repair

Abstract

Aim: This study aimed to elucidate the role of regulator of chromosome condensation 1 (RCC1) in colorectal cancer (CRC) progression, as well as its involvement in chemoresistance. We specifically examined how RCC1 knockdown modulates cellular responses, including cell cycle, apoptosis, and senescence induced by 5-fluorouracil (5-FU) or doxorubicin (Doxo) in both parental and drug-resistant CRC cell lines. Additionally, we assessed the potential of RCC1 inhibition as an adjuvant therapeutic strategy to enhance the efficacy of chemoradiotherapy in CRC.

Methods: The expression of RCC1 in colon cancer tissues and corresponding adjacent non-cancerous tissues was evaluated through tissue microarrays, and its correlation with characteristics and patient prognosis was also examined. Subsequently, a series of in vivo and in vitro experiments based on parental and drug-resistant CRC cell lines were conducted to assess the impact of RCC1 knockdown on sensitivity to 5-FU or Doxo. Finally, transcriptomic analysis and subsequent validation assays were performed to explore the underlying molecular mechanisms.

Results: RCC1 knockdown significantly enhanced the antitumor efficacy of 5-FU and Doxo in both CRC and drug-resistant CRC cells. In xenograft models, RCC1 knockdown in combination with 5-FU or Doxo suppressed tumor growth with no evident systemic toxicity observed. Transcriptomic profiling and experimental verification revealed that RCC1 knockdown may impair DNA repair by downregulating key repair proteins, thereby leading to more severe and sustained DNA damage.

Conclusion: Our results indicate that RCC1 downregulation enhances the responsiveness of both parental and drug-resistant CRC cells to 5-FU and Doxo, highlighting its potential as a therapeutic adjunct to improve clinical outcomes in CRC.

Keywords

RCC1 / 5-fluorouracil / doxorubicin / colorectal cancer / chemoresistance / DNA damage response

References

[1] Bray F,Sung H.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024;74:229-63

[2] Sonkin D,Teicher BA.Cancer treatments: past, present, and future.Cancer Genet2024;286-7:18-24 PMCID:PMC11338712

[3] Hu Z,Ma Z.Quantitative evidence for early metastatic seeding in colorectal cancer.Nat Genet2019;51:1113-22 PMCID:PMC6982526

[4] Van Cutsem E, Nordlinger B, Cervantes A; ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment.Ann Oncol2010;21 Suppl 5:v93-7

[5] Chen P,Lin X,Zhang S.Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism.Mol Ther Oncolytics2021;20:228-39 PMCID:PMC7873577

[6] Yao CW,Piao MJ.Reduced autophagy in 5-fluorouracil resistant colon cancer cells.Biomol Ther2017;25:315-20 PMCID:PMC5424642

[7] Gmeiner WH.Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects.Cancer Drug Resist2023;6:257-72 PMCID:PMC10344727

[8] Sethy C.5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition.Biomed Pharmacother2021;137:111285

[9] Li S,Yang X.Corilagin enhances the anti-tumor activity of 5-FU by downregulating the expression of GRP 78.Sci Rep2023;13:22661 PMCID:PMC10730900

[10] Gao L,Yu M.Colon cancer cells treated with 5-fluorouracil exhibit changes in polylactosamine-type N-glycans.Mol Med Rep2014;9:1697-702

[11] Azwar S,Abdullah M,Mohtarrudin N.Recent updates on mechanisms of resistance to 5-fluorouracil and reversal strategies in colon cancer treatment.Biology2021;10:854 PMCID:PMC8466833

[12] Nakagawa Y,Takahashi A.The BRCA2 gene is a potential molecular target during 5-fluorouracil therapy in human oral cancer cells.Oncol Rep2014;31:2001-6

[13] Groelly FJ,Dagg RA,Tarsounas M.Targeting DNA damage response pathways in cancer.Nat Rev Cancer2023;23:78-94

[14] Bierbaum M.Cell cycle-dependent binding modes of the ran exchange factor RCC1 to chromatin.Biophys J2013;104:1642-51 PMCID:PMC3627872

[15] Jing L.The intricate roles of RCC1 in normal cells and cancer cells.Biochem Soc Trans2022;50:83-93

[16] Cekan P,Pan Y.RCC1-dependent activation of Ran accelerates cell cycle and DNA repair, inhibiting DNA damage-induced cell senescence.Mol Biol Cell2016;27:1346-57 PMCID:PMC4831887

[17] Bannoura SF,Khan HY.RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth.Cancer Lett2024;604:217275 PMCID:PMC11471368

[18] Liu H.CRISPR screening and cell line IC50 data reveal novel key genes for trametinib resistance.Clin Exp Med2024;25:21 PMCID:PMC11663197

[19] Zhang K,Jamalzadeh S.Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer.Sci Adv2022;8:eabm1831 PMCID:PMC8865800

[20] Deng Y,Zhao Y.RCC1 expression as a prognostic marker in colorectal liver oligometastases.Pathol Oncol Res2021;27:1610077 PMCID:PMC8674189

[21] Qiao L,Tian Y.Regulator of chromatin condensation 1 abrogates the G1 cell cycle checkpoint via Cdk1 in human papillomavirus E7-expressing epithelium and cervical cancer cells.Cell Death Dis2018;9:583 PMCID:PMC5964113

[22] Hou X,Liu R,Zhang W.Phosphorylation of RCC1 on serine 11 facilitates G1/S transition in HPV E7-expressing cells.Biomolecules2021;11:995 PMCID:PMC8301946

[23] Zhuang M,Liang H.Targeting RCC1 to block the human soft-tissue sarcoma by disrupting nucleo-cytoplasmic trafficking of Skp2.Cell Death Dis2024;15:241 PMCID:PMC10985091

[24] Renault L,Henkel A.Structural basis for guanine nucleotide exchange on Ran by the regulator of chromosome condensation (RCC1).Cell2001;105:245-55

[25] Huang T,Song X.PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells.Mol Cell2021;81:1276-91.e9 PMCID:PMC7979509

[26] Liu Y,Tavana O.Understanding the complexity of p53 in a new era of tumor suppression.Cancer Cell2024;42:946-67 PMCID:PMC11190820

[27] Aubrey BJ,Janic A,Strasser A.How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?.Cell Death Differ2018;25:104-13 PMCID:PMC5729529

[28] Feng L,Xu Y.Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence.Cell Cycle2006;5:2812-9

[29] Okamura S,Tanaka T.p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis.Mol Cell2001;8:85-94

[30] Oda K,Tanaka T.p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53.Cell2000;102:849-62

[31] Maiuthed A,Erlenbach-Wuensch K.Cytoplasmic p21 mediates 5-fluorouracil resistance by inhibiting pro-apoptotic Chk2.Cancers2018;10:373 PMCID:PMC6210175

[32] Yang H,Hampel C.ATF2 loss promotes 5-FU resistance in colon cancer cells via activation of the ATR-Chk1 damage response pathway.BMC Cancer2023;23:480 PMCID:PMC10223906

[33] Huang RX.DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer.Signal Transduct Target Ther2020;5:60 PMCID:PMC7192953

[34] Shimada E,Nakagawa M.Methylation-mediated silencing of protein kinase C zeta induces apoptosis avoidance through ATM/CHK2 inactivation in dedifferentiated chondrosarcoma.Br J Cancer2022;126:1289-300 PMCID:PMC9042856

[35] Joe Y,Yang S.ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis.J Biol Chem2006;281:28764-71

[36] Rogoff HA,Frame FM.Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2.Mol Cell Biol2004;24:2968-77 PMCID:PMC371110

[37] Stevens C,La Thangue NB.Chk2 activates E2F-1 in response to DNA damage.Nat Cell Biol2003;5:401-9

[38] Yang S,Bisi JE.PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2.Nat Cell Biol2002;4:865-70

[39] Chen WS,Yu YC.Enhancement of p53-mutant human colorectal cancer cells radiosensitivity by flavonoid fisetin.Int J Radiat Oncol Biol Phys2010;77:1527-35

[40] Hsieh CC,Lin CY.CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer.Br J Cancer2022;127:1615-28 PMCID:PMC9596403

[41] Martin SA.Cellular commitment to reentry into the cell cycle after stalled DNA is determined by site-specific phosphorylation of Chk1 and PTEN.Mol Cancer Ther2008;7:2509-16 PMCID:PMC4979322

[42] Liu Y,Perdreau SA.Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.Cancer Res2007;67:2685-92

[43] Siddiqui MS,Fenech MF.Persistent γH2AX: a promising molecular marker of DNA damage and aging.Mutat Res Rev Mutat Res2015;766:1-19

[44] Carvalho JF.Targeting homologous recombination-mediated DNA repair in cancer.Expert Opin Ther Targets2014;18:427-58

[45] Karanam K,Loewer A.Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid S phase.Mol Cell2012;47:320-9 PMCID:PMC3494418

[46] Cybulla E.Leveraging the replication stress response to optimize cancer therapy.Nat Rev Cancer2023;23:6-24 PMCID:PMC9789215

[47] Drew Y,Curtin NJ.DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications.Nat Rev Drug Discov2025;24:19-39

[48] Fradet-Turcotte A,Grapton D.BRCA2 functions: from DNA repair to replication fork stabilization.Endocr Relat Cancer2016;23:T1-17

[49] Schlacher K,Jasin M.A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2.Cancer Cell2012;22:106-16 PMCID:PMC3954744

[50] Lomonosov M,Sangrithi M,Venkitaraman AR.Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein.Genes Dev2003;17:3017-22 PMCID:PMC305253

[51] Neal FE,Uhrig ME.Distinct roles of the two BRCA2 DNA-binding domains in DNA damage repair and replication fork preservation.Cell Rep2025;44:115654 PMCID:PMC12129652

[52] Salunkhe S,Kaur H.Promotion of DNA end resection by BRCA1-BARD1 in homologous recombination.Nature2024;634:482-91 PMCID:PMC11539920

[53] Ceppi I,Mütze M.Mechanism of BRCA1-BARD1 function in DNA end resection and DNA protection.Nature2024;634:492-500 PMCID:PMC11464378

[54] Tarsounas M.The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.Nat Rev Mol Cell Biol2020;21:284-99 PMCID:PMC7204409

[55] Li X.Homologous recombination in DNA repair and DNA damage tolerance.Cell Res2008;18:99-113 PMCID:PMC3087377

[56] Matos-Rodrigues G,Muhammad AA.In vivo reduction of RAD51-mediated homologous recombination triggers aging but impairs oncogenesis.EMBO J2023;42:e110844 PMCID:PMC10577633

[57] Xu X,Guo R.Fanconi anemia proteins participate in a break-induced-replication-like pathway to counter replication stress.Nat Struct Mol Biol2021;28:487-500

[58] Engel JL,Wu M.The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance.Cell2024;187:6055-70.e22 PMCID:PMC11490392

[59] Erdemir Sayan S, Sreekumar R, Bhome R, Mirnezami A, Yagci T, Sayan AE. ERCC1 abundance is an indicator of DNA repair-apoptosis decision upon DNA damage.Cell Death Discov2024;10:47 PMCID:PMC10810800

[60] Lehmann J,Smolorz S,Emmert S.XPF knockout via CRISPR/Cas9 reveals that ERCC1 is retained in the cytoplasm without its heterodimer partner XPF.Cell Mol Life Sci2017;74:2081-94 PMCID:PMC11107539

[61] Luo Y,Su X.A selective RCC1 inhibitor loaded in membrane-coated DNA nanocage for targeted suppression of TNBC progression.Mater Today Bio2025;34:102232 PMCID:PMC12441726